CJC-IPA 5+5

Description

CJC-IPA 5+5 is a combined research preparation containing 5 mg of CJC-1295 with Drug Affinity Complex (DAC) and 5 mg of Ipamorelin, co-lyophilized in a single vial for experimental convenience. CJC-1295 is a 29-amino-acid GHRH analogue modified with DAC technology to extend plasma half-life by forming a reversible covalent bond with serum albumin; Ipamorelin is a selective, third-generation ghrelin receptor (GHSR-1a) agonist with high specificity for pituitary GH secretion and minimal corticotroph cross-reactivity. Together, they target complementary receptor systems, making this combination a valuable dual-agonist probe for studying pulsatile versus tonic growth hormone release kinetics and downstream IGF-1 axis modulation in cell and animal model systems.

Dorado Research supplies CJC-IPA 5+5 as a precisely formulated, lyophilized dual-peptide preparation with identity and purity of each component confirmed by RP-HPLC and ESI-MS before packaging. The material is intended solely as a laboratory research reference standard for in vitro receptor pharmacology, secretagogue interaction studies, and neuroendocrine axis investigations. For laboratory research use only. Not for human or veterinary use.